HI
DNA icon

Hudock Inc’s Ginkgo Bioworks DNA Stock Holding History

Hudock Inc’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50
Closed -$6K – 280
2022
Q3 		$6K Hold
50
– – ﹤0.01% 577
2022
Q2 		$4K Hold
50
– – ﹤0.01% 604
2022
Q1 		$8K Buy
50
+25
+100% +$4.87K ﹤0.01% 557
2021
Q4 		$8K Hold
25
– – ﹤0.01% 558
2021
Q3 		$11K Buy
+25
New +$12.2K ﹤0.01% 544

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Hudock Inc's DNA Position: Q4 2022 in Review

Hudock Inc sold out of Ginkgo Bioworks (DNA) in Q4 2022, closing a stake of 50 shares — an estimated $6K sold.

Hudock Inc first reported a position in DNA in Q3 2021 and held it in 5 quarters. The position peaked at $11K in Q3 2021. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

  • Hudock Inc reported no remaining Ginkgo Bioworks position as of Q4 2022 after selling out during the quarter.
  • Hudock Inc sold 50 Ginkgo Bioworks shares in Q4 2022, an estimated $6K.
  • Hudock Inc first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 5 quarters.
  • Hudock Inc's Ginkgo Bioworks position peaked at $11K in Q3 2021.
  • 320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on Hudock Inc's 13F filing for Q4 2022, filed 8 Feb 2023.